BANAN (cefpodoxime proxetil) by Daiichi Sankyo is clinical pharmacology absorption and excretion: cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Approved for development of drug-resistant bacteria, maintain the effectiveness of cefpodoxime proxetil, other antibacterial drugs and 3 more indications. First approved in 1992.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
BANAN (cefpodoxime proxetil) is an oral third-generation cephalosporin antibiotic indicated for bacterial infections caused by susceptible organisms. It is a prodrug absorbed from the GI tract and de-esterified to its active metabolite cefpodoxime, which exhibits bactericidal activity by inhibiting bacterial cell wall synthesis. The drug demonstrates broad-spectrum coverage with pediatric and adult formulations available.
Product is in late lifecycle phase with declining revenue expectations; marketing and field teams likely consolidating or transitioning to support generic transition.
CLINICAL PHARMACOLOGY Absorption and Excretion: Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the…
Worked on BANAN at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients.
Coolsculpting With Cooltone Verses Coolsculpting Alone for the Banana Roll Area
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
Positions linked to BANAN are primarily defensive and transition-focused, supporting market management during generic erosion rather than growth initiatives. Career development potential is constrained by the product's LOE status and lack of clinical pipeline support, making this role suitable mainly for stabilization-focused professionals or those seeking transition experience.